Compare ZCMD & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZCMD | NXL |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | China | United States |
| Employees | N/A | 8 |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 7.2M |
| IPO Year | 2019 | N/A |
| Metric | ZCMD | NXL |
|---|---|---|
| Price | $0.11 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.1M | 754.0K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.52 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.31 |
| 52 Week High | $2.29 | $2.00 |
| Indicator | ZCMD | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 12.24 | 78.78 |
| Support Level | N/A | $0.35 |
| Resistance Level | $0.71 | $0.69 |
| Average True Range (ATR) | 0.25 | 0.06 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 1.49 | 98.48 |
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.